间变性少突胶质细胞瘤治疗模式的生存分析:单中心回顾性研究
该单中心回顾性分析纳入1996至2016年40例经分子确诊的1p19q共缺失间变性少突胶质细胞瘤患者,比较术后放疗联合化疗与单纯辅助化疗的生存差异。
要点
- 单纯辅助化疗组疾病进展风险约为放疗联合化疗组的5倍
- 两组总生存无显著差异,中位总生存尚未达到
- 年龄、KPS、切除程度及放疗时机与生存改善无关
核心结论
- 术后单纯辅助化疗而非放疗联合化疗,可能是部分间变性少突胶质细胞瘤患者的选择,总生存相似但无进展生存缩短。
研究设计与样本
- 单中心回顾性分析,纳入1996至2016年诊断为间变性少突胶质细胞瘤的患者159例,其中40例原发诊断且记录1p19q共缺失,中位随访7.1年(范围0.6-16.7年)。
主要发现
- 术后45%患者接受放疗联合化疗,50%接受单纯辅助化疗。
- 单纯化疗组接受化疗周期数多于放疗联合化疗组的趋势(P=0.051)。
- 单纯化疗与放疗联合化疗组总生存无显著差异(P=0.8)。
- 单因素分析显示年龄、KPS、切除程度或放疗时机与生存改善无关。
关键数值与推荐
- 间变性少突胶质细胞瘤分子定义:1p19q共缺失。
- 术后45%接受放疗联合化疗,50%接受单纯辅助化疗。
- 总生存比较P=0.8。
- 化疗周期数比较P=0.051。
临床怎么用
- 对于部分间变性少突胶质细胞瘤患者,可考虑术后单纯辅助化疗以平衡放疗远期毒性,但需告知无进展生存可能缩短。
局限性
- 单中心回顾性设计,样本量有限(40例分子确诊患者),选择偏倚可能存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion. There is no curative therapy, and standard of care includes surgical resection followed by radiation and chemotherapy. However, the benefit of up-front radiation with chemotherapy compared to chemotherapy alone has not been demonstrated in a randomized control trial. Given the potential long-term consequences of radiation therapy, such as cognitive impairment, arteriopathy, endocrinopathy, and hearing/visual impairment, there is an effort to balance longevity with radiation toxicity. METHODS: We performed a retrospective single institution analysis of survival of patients with anaplastic oligodendroglioma over 20 years. RESULTS: 159 patients were identified as diagnosed with an anaplastic oligodendroglioma between 1996 and 2016. Of those, 40 patients were found to have AO at original diagnosis and had documented 1p19q co-deletion with a median of 7.1 years of follow-up (range: 0.6-16.7 years). After surgery, 45 % of patients were treated with radiation and chemotherapy at diagnosis, and 50 % were treated with adjuvant chemotherapy alone. The group treated with chemotherapy alone had a trend of receiving more cycles of chemotherapy than patients treated with radiation and chemotherapy upfront (p = 0.051). Median overall survival has not yet been reached. The related risk of progression in the upfront, adjuvant chemotherapy only group was almost 5-fold higher than the patients who received radiation and chemotherapy (hazard ratio = 4.85 (1.74-13.49), p = 0.002). However, there was no significant difference in overall survival in patients treated with upfront chemotherapy compared to patients treated upfront with chemotherapy and radiation (p = 0.8). Univariate analysis of age, KPS, extent of resection, or upfront versus delayed radiation was not associated with improved survival. CONCLUSIONS: Initial treatment with adjuvant chemotherapy alone, rather than radiation and chemotherapy, may be an option for some patients with anaplastic oligodendroglioma, as it is associated with similar overall survival despite shorter progression free survival.
引用
- Bush NAO, Young JS, Zhang Y, et al. A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol. 2021. PMID: 34125374. doi:10.1007/s11060-021-03781-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。